How common is haematoma after breast augmentation, and what do the figures mean?

Bleeding control is part of every operation, but a postoperative haematoma is a different outcome from a small amount of blood estimated during surgery or fluid collected in a drain. A haematoma is a collection of blood in or around the operative pocket, diagnosed clinically or by imaging; some collections are observed, while others need urgent treatment or another operation. Research rates depend on what a study counted, how long it followed patients and which procedures it included. Creating an implant pocket involves separating tissue planes, which can expose small blood vessels; bleeding control means identifying and sealing active sources during the operation. This is distinct from a drain, which collects fluid afterwards and cannot itself show whether bleeding has stopped or whether a haematoma is present. Electrocautery uses electrical energy to heat tissue, while ultrasonic instruments use vibration to cut and coagulate tissue; both are approaches to dissection and haemostasis, not proof that a particular device prevents a later haematoma. The rationale for careful haemostasis is clinically plausible, but comparative observational findings do not establish that an instrument or technique eliminates risk. [4] [9]

How often is a postoperative haematoma reported?

A 2021 evidence review included 28 studies of non-oncological breast procedures and reported haematoma rates of 0.2% to 5.7% for breast augmentation. This is a range across heterogeneous studies, not a single pooled estimate or a personal prediction. The review found evidence about pocket choice and incision location inconclusive, and found insufficient evidence for several other proposed risk factors. It also considered augmentation-mastopexy and breast reduction, whose rates should not be substituted for augmentation-only estimates. [1]

A retrospective cohort from one private clinic reviewed 1,128 women undergoing primary augmentation from 2012 to 2019 without pocket irrigation. The authors recorded postoperative haematoma in 30 patients (2.7%). The median time to diagnosis was 14 hours, with an interquartile range from 5 hours to 9 days. Six patients (0.5%) developed a deep surgical-site infection; that is a separate outcome, not another haematoma count. Age, BMI, implant volume and implant placement were not significantly associated with haematoma in this cohort. The findings support planning for follow-up in the early postoperative period, but one clinic’s retrospective records cannot define the rate for every setting. [2]

A smaller retrospective analysis of 132 primary bilateral procedures, including augmentation-mastopexy, identified nine cases of postoperative bleeding (6.8%). The estimate is higher than the review range, but the study used a mixed procedure group, a small denominator and a different setting and definition. Several factors were associated in univariate analysis, yet none remained an independent risk factor in the multivariable analysis. These results do not establish that fluid administration, anaesthesia type or blood pressure caused bleeding. [5]

Can pocket-plane studies be compared?

Two reviews reached different-looking conclusions using different evidence sets. A 2024 systematic review included 10 comparative studies of subfascial versus subglandular placement; four contributed to its haematoma comparison. It reported a statistically significant difference favouring the subfascial plane, but judged all included studies at high risk of bias. The abstract does not provide the underlying event counts or effect size, so those values are not inferred here. [3]

A 2026 systematic review and meta-analysis examined primary augmentation only, excluding revision surgery, augmentation-mastopexy and reconstruction. It included 91 studies and 51,524 patients overall, but the denominator available for haematoma differed by plane: subglandular 1,624, subfascial 3,506, submuscular 9,601 and dual-plane 8,053. Separately pooled haematoma proportions were 1.2% (95% CI 0.7–2.4), 1.0% (0.59–1.67), 0.8% (0.6–1.18) and 0.9% (0.75–1.15), respectively. These are pooled proportions from different contributing studies, not a randomised head-to-head trial. In a direct subfascial-versus-subglandular analysis, the relative risk was 0.21 (95% CI 0.02–2.31; P=0.20), which did not show a statistically reliable difference. The broad confidence interval is compatible with substantial benefit, little difference or harm. The authors note that the evidence base is predominantly observational and heterogeneous. [4]

The two reviews are not interchangeable: one focused on a narrower plane comparison and included high-bias studies; the newer review included more primary augmentation evidence but still found no statistically reliable direct reduction for subfascial versus subglandular placement. Neither establishes a universally safest plane. Anatomy, tissue coverage and the operation planned matter to clinical decisions; the pooled percentages should not be used to choose a technique for an individual.

Blood loss and drain output measure different things

Estimated intra-operative blood loss is recorded during an operation; it is not a later diagnosis of a pocket haematoma. Drain output is the volume collected after surgery and may contain blood mixed with tissue fluid. A larger drain total does not by itself mean that a clinically significant haematoma occurred, and low output cannot rule one out.

A retrospective study compared transaxillary endoscopic augmentation using conventional electrocautery in 81 patients with ultrasonic-scalpel dissection in 92 patients, all operated on by one senior surgeon and team. The paper reports estimated blood loss as 21.59 ± 6.44 mL with electrocautery and 18.67 ± 6.20 mL with the ultrasonic scalpel. Mean total drain volume was much larger: 232.37 ± 99.15 mL and 122.24 ± 43.81 mL, respectively. Mean drain duration was 3.77 ± 1.10 days versus 2.52 ± 0.54 days. The accessible abstract does not identify what the ± values represent, so they are reproduced without labelling them as standard deviations. The study was retrospective, specific to one transaxillary technique and compared instrument groups that may differ in other ways; it does not prove that one device prevents haematoma generally. The contrast between millilitres of estimated blood loss and total drainage illustrates why these figures must not be treated as the same outcome. Although the records covered procedures from January 2018 to December 2020 and pain scores were collected for three postoperative days, the accessible abstract does not specify the follow-up window used to ascertain haematoma or other complications. [6]

A 2026 primary-augmentation meta-analysis also found that reported drain use varied among the contributing studies. Drain practice, collection period, fluid composition and thresholds for removal are not uniform, so drain volumes cannot be compared as if they were a common measure of blood loss or a clinical haematoma rate. [4]

Clinical assessment and warning signs

After surgery, expected bruising and swelling can overlap with early signs of bleeding. A developing haematoma may be considered when there is unusual or rapidly increasing swelling, a breast that becomes tighter or more painful, marked new asymmetry or a change in skin colour. Symptoms alone cannot confirm the cause; the clinical team may need to examine the breast and decide whether imaging or treatment is appropriate.

Sudden or worsening swelling, unexpected pain or a colour change after breast enlargement surgery warrants prompt contact with the treating clinic, as NHS guidance advises. [8] Heavy wound bleeding, rapidly progressive swelling, faintness, severe weakness, chest pain or difficulty breathing needs urgent medical assessment; use local emergency services for severe symptoms. Do not wait for a routine review if symptoms are escalating. NHS breast-enlargement guidance.

Haematoma and return to theatre are also not synonyms. A study may count any diagnosed collection, while only a subset needs evacuation or another operation. The 1,128-patient cohort reports 30 haematomas but its abstract does not state how many were evacuated; this review therefore does not convert that count into a reoperation rate. Studies of reconstruction should be kept separate too: a case report of a delayed capsular bleed seven years after mastectomy reconstruction describes a different patient group and cannot estimate early augmentation risk. [2] [7]

Planning follow-up and asking clear questions

Before surgery, ask what the team means by “bleeding” or “haematoma” in its outcome figures: any diagnosed collection, a collection requiring drainage, or a return to theatre? Ask about the time period and patient group behind the quoted rate, including whether it concerns primary augmentation alone or combines it with mastopexy or reconstruction. The breast augmentation cost in Turkey should be considered alongside the scope of the quoted clinical care and follow-up arrangements.

Clarify who can assess a new symptom after discharge, how to reach that person outside routine hours, when planned reviews occur and how care is coordinated if the patient is travelling. If comparing a breast augmentation package, ask whether it specifies post-operative review, urgent assessment and arrangements for a complication, rather than assuming those services from the package label. Just Clinic Istanbul is an independent marketing and lead generation platform, not a healthcare provider or medical tourism intermediary. Enquiries may be shared with authorised healthcare partners with consent.

• How does the team define and record a haematoma, and how many patients in the quoted denominator had one?
• Are the figures for primary augmentation alone, or do they include mastopexy, revisions or reconstruction?
• Which warning signs should prompt an immediate call, and what number is available outside normal hours?
• Who will assess symptoms after discharge, and what follow-up is planned during the first day and later?
• If a haematoma is suspected, what assessment and treatment options may be considered?
• What clinical follow-up and urgent-care arrangements are included in the proposed plan or package?

References

1. Daar DA, Bekisz JM, Chiodo MV, DeMitchell-Rodriguez EM, Saadeh PB. “Hematoma After Non-Oncologic Breast Procedures: A Comprehensive Review of the Evidence.” Aesthetic Plastic Surgery. 2021;45(6):2602–2617 (December 2021 issue); published online 16 April 2021. DOI: 10.1007/s00266-021-02276-6; PMID: 33864116.
2. Hemmingsen MN, Larsen A, Ørholt M, Rasmussen LE, Weltz TK, Andersen PS, Sarmady F, Elberg JJ, Vester-Glowinski PV, Herly M. “Hematoma and deep surgical site infection following primary breast augmentation: A retrospective review of 1128 patients.” Journal of Plastic, Reconstructive & Aesthetic Surgery. 2022;75(3):1197–1203 (March 2022 issue); published online 27 November 2021. DOI: 10.1016/j.bjps.2021.11.067; PMID: 34924323.
3. Yuan M, Kim P, Gallo L, Austin RE, Lista F, Ahmad J. “Outcomes in Subfascial Versus Subglandular Planes in Breast Augmentation: A Systematic Review and Meta-analysis.” Aesthetic Surgery Journal. 2024;44(9):NP639–NP644 (September 2024 issue); published online 3 June 2024. DOI: 10.1093/asj/sjae118; PMID: 38825810.
4. Alderhali R, Jamel WA, Dehnadi S, Seth I, Khajuria A. “Implant Pocket Plane Selection in Primary Breast Augmentation: A Meta-Analysis and Systematic Review of Complication Profiles.” Aesthetic Plastic Surgery. 2026;50(11):3979–3987 (June 2026 issue); published online 26 February 2026. DOI: 10.1007/s00266-026-05706-5; PMID: 41748776; full text: PMC13315495.
5. Richard P, Huesler R, Banic A, Erni D, Plock JA. “Perioperative risk factors for haematoma after breast augmentation.” Journal of Plastic Surgery and Hand Surgery. 2013;47(2):130–134 (April 2013 issue); published online 13 February 2013. DOI: 10.3109/2000656X.2012.740675; PMID: 23402583.
6. Xie Z, Yan K, Qu Y, Gao S, Lu T, Hu C, Wang S, Shangguan W, Wu G. “A Retrospective Study of Transaxillary Endoscopic Breast Augmentation Using Ultrasonic Scalpel or Conventional Electrocautery for Implant Pocket Dissection.” Aesthetic Plastic Surgery. 2024;48(10):1949–1955 (May 2024 issue); published online 25 August 2023. DOI: 10.1007/s00266-023-03569-8; PMID: 37626139.
7. Seth AK, Kim JYS. “Acute symptomatic hematoma with defined etiology seven years after breast reconstruction: A case report and literature review.” Canadian Journal of Plastic Surgery. 2010;18(2):e27–e29 (June 2010 issue); published online 1 June 2010. DOI: 10.1177/229255031001800201; PMID: 21629619; full text: PMC2933100.
8. National Health Service (NHS). “Breast enlargement (implants).” NHS. Page last reviewed 21 September 2023; accessed 18 October 2026. https://www.nhs.uk/tests-and-treatments/cosmetic-procedures/cosmetic-surgery/breast-enlargement/. Guidance advises contacting the treating clinic as soon as possible for unexpected pain, unusual swelling or skin-colour changes.
9. Matthews B, Nalysnyk L, Estok R, Fahrbach K, Banel D, Linz H, Landman J. “Ultrasonic and Nonultrasonic Instrumentation: A Systematic Review and Meta-analysis.” Archives of Surgery. 2008;143(6):592–600. Published online 16 June 2008. DOI: 10.1001/archsurg.143.6.592; PMID: 18559754. Full text.